XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
A summary of the stock option activity under the Company’s equity plans and inducement awards, for the nine months ended September 30, 2021 is as follows:
(number of shares in millions)Number
of
Shares
Weighted
Average
Exercise
Price
Options outstanding at December 31, 20205.2 $23.24 
Options granted— $— 
Less:
Options exercised(3.6)$24.26 
Options canceled or expired(0.1)$25.03 
Options outstanding at September 30, 20211.5 $20.57 
Options exercisable at September 30, 20211.1 $23.20 
Schedule of Restricted Stock Unit Activity
A summary of the RSU activity under the Company’s equity plans and inducement awards, including RSU awards with performance metrics, for the nine months ended September 30, 2021 is as follows:
(number of shares in millions)Number
of
Shares
Weighted
Average
Grant Date
Fair Value
RSUs outstanding at December 31, 20203.2 $20.56 
RSUs granted1.7 $29.95 
Less:
RSUs vested(0.8)$24.00 
RSUs canceled(0.7)$24.63 
RSUs outstanding at September 30, 20213.4 $23.91 
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) was allocated as follows:
Three months ended
September 30,
Nine months ended
September 30,
(in millions)2021202020212020
Cost of molecular diagnostic testing$0.4 $0.3 $1.1 $1.0 
Cost of pharmaceutical and clinical services— 0.1 0.1 0.3 
Research and development expense0.8 1.3 3.3 3.6 
Selling, general, and administrative expense8.8 6.7 23.4 12.9 
     Total stock-based compensation expense$10.0 $8.4 $27.9 $17.8